Multidisciplinary Team Approaches for the Management of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the advancement of diagnostic tools and therapeutic options, the management of HCC has improved remarkably. However, the majority of patients with HCC are diagnosed at an advanced stage and overall prognosis is still grave. Major milestones have occurred in the management of advanced HCC after the introduction of the molecular targeted therapy (MTX). Owing to emerging new targeted therapeutic agents in first-line and second-line settings, HCC seemed to be manageable. In addition, immune checkpoint inhibitors (ICI) are also an attractive choice for the treatment of HCC. Although emerging systemic therapeutic agents may have shifted the treatment paradigm for HCC, there is still an unmet need for effective systemic therapy as monotherapy. Recently, ICI-based combination therapy is expected to improve therapeutic efficacy for HCC. Given the complex nature of the treatment strategy of advanced HCC, optimal treatment of HCC remains complex despite the treatment guidelines for HCCs. Although there are guidelines for the management of HCC, optimal care of HCC remains complex because of the complexity of managing HCC. Multidisciplinary team approaches using multimodality treatment are therefore used in the management of HCC.